Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers identify genetic markers to predict response to chemotherapy for colorectal cancer

07.06.2004


One of the most common challenges facing oncologists today is determining the best course of treatment for their patients - one that would be effective and have the fewest possible side effects. In a study presented today at the 40th Annual Meeting of the American Society of Clinical Oncology in New Orleans, Fox Chase Cancer Center researchers have identified genetic markers in the blood that can help predict a patient’s response to and side effects from irinotecan, a common chemotherapy drug for colorectal cancer.



Leslie E. Carlini, Ph.D., a research associate in the Fox Chase laboratory of Rebecca L. Blanchard, Ph.D., presented the findings. Their research focuses on genetic variations that influence the effect of medicines on different people - an area of study called pharmacogenetics. Ultimately, the goal is to improve the way drugs are prescribed by identifying individuals who are likely to benefit from a specific medicine or who are at increased risk of serious side effects.

"Our data suggest that variations in genes that help metabolize irinotecan may be useful predictors of how well colorectal cancer patients respond to this drug and how severe side effects will be," Carlini said.


To see how genetic variations affected response and side effects, the laboratory analyzed DNA in blood samples taken during a multi-site clinical trial to test an investigational combination chemotherapy regimen for metastatic colorectal cancer. The patients received intravenous irinotecan once a week and twice-daily tablets of the drug capecitabine for two weeks of a three-week treatment cycle.

The researchers looked at a family of genes called UGTs (UDP-glucuronosyltransferases), involved in breaking down irinotecan within the body and ultimately disposing of it. "Our research indicates that patients specific UGT1A7 or UGT1A9 genotypes will get more anti-tumor response from the chemotherapy combination. What’s more, these patients should have fewer side effects," Carlini said.

There were no statistically significant associations between the other two UGT genes and either side effects or antitumor response. "In reality, physicians will soon be able to personalize cancer therapies based on the tumor’s characteristics and the genetic profile of the person," said Carlini. "The ultimate goal is to tailor treatment that offers the most anti-tumor activity with the fewest side effects."

In a separate study based on the same clinical trial, Fox Chase researchers also discovered a protein marker to help predict response to combination chemotherapy with capecitabine and irinotecan. Medical oncologist Neal J. Meropol will present these results at the ASCO annual meeting in a Gastrointestinal (Colorectal) Cancer Session on Sunday, June 6 between 8 a.m. and 12 noon (Abstract # 3520, Poster #11).

In addition to Blanchard and Meropol, Carlini’s colleagues in the study include Y.-M. Chen, Ph.D., T. Hill, and C. McGarry of Roche Labs, Nutley, N.J.; and P. J. Gold, M.D., of the Swedish Cancer Institute, Seattle, Wash.


Fox Chase Cancer Center was founded in 1904 in Philadelphia, Pa., as the nation’s first cancer hospital. In 1974, Fox Chase became one of the first institutions designated as a National Cancer Institute Comprehensive Cancer Center. Fox Chase conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center’s web site at www.fccc.edu or call 1-888-FOX CHASE.

Karen C. Mallet | EurekAlert!
Further information:
http://www.fccc.edu/
http://www.fccc.edu

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

DGIST develops 20 times faster biosensor

24.04.2017 | Physics and Astronomy

Nanoimprinted hyperlens array: Paving the way for practical super-resolution imaging

24.04.2017 | Materials Sciences

Atomic-level motion may drive bacteria's ability to evade immune system defenses

24.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>